Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

The Lancet

Topics

Medicine

Cancer Oncology

Immunology

Internal Medicine

Infectious Diseases

Show all topics

DOI

10.1016/s0140-6736(20)31208-3

License

other-oa